Glaukos (GKOS) Q4 2025: iDose-TR Drives 53% U.S. Glaucoma Growth, Epioxa Launch Sets Up 2H Surge

2026-02-17 | By EarningsIQ Research

Glaukos’ Q4 showcased breakout momentum in U.S. glaucoma, powered by iDose-TR, while the Epioxa launch in corneal health positions the company for a second-half 2026 inflection. Strategic investments in patient access, payer engagement, and pipeline development are reshaping the ophthalmic landscape and setting a foundation for multi-year growth.

Summary

• iDose-TR Adoption Expands: U.S. glaucoma franchise accelerates as repeat dosing and broader utilization gain traction.
• Epioxa Launch Catalyzes Corneal Health: Early site deployment and payer engagement set up a back-half revenue ramp.
• Strategic Capital Allocation: Investments balance near-term launch costs with a clear path to operating leverage and cash flow inflection.

Performance Analysis

Glaukos delivered record quarterly and annual sales, driven by robust execution across its glaucoma and corneal health franchises. The U.S. glaucoma business, representing the company’s largest revenue stream, saw standout growth propelled by iDose-TR, a sustained-release implant for intraocular pressure management. iDose-TR sales comprised over half of U.S. glaucoma revenue in Q4, reflecting strong physician adoption and positive clinical outcomes. The corneal health segment, while smaller, is set for a transformation with the FDA approval and imminent launch of Epioxa, a novel topical therapy for keratoconus, which is expected to address significant unmet need.

International glaucoma delivered steady growth despite anticipated competitive headwinds, while operational investments in market access and patient support underpinned long-term positioning. Management reaffirmed full-year 2026 guidance, projecting continued double-digit growth, with a particular emphasis on sequential improvements in iDose-TR and a back-half acceleration in corneal health as Epioxa’s reimbursement and site network mature.

• U.S. Glaucoma Outperformance: iDose-TR adoption drove 53% YoY growth in the segment, with repeat dosing and broader payer access emerging as incremental levers.
• Corneal Health Transition: Epioxa approval and launch investments are expected to drive volatility in early 2026, with a pronounced revenue ramp once the permanent J-code takes effect in Q3.
• International Growth Moderates: High single-digit growth outlook reflects both competitive trialing and offsetting new product launches in key overseas markets.

Operating expense growth will be elevated in 2026 to support launches and pipeline, but management targets operating leverage and cash flow break-even by year-end.

Executive Commentary

Strategic Positioning

1. iDose-TR: Early Adoption Curve and Repeat Dosing

iDose-TR, sustained-release glaucoma implant, is rapidly becoming the cornerstone of Glaukos’ U.S. glaucoma franchise. The recent FDA label expansion allowing unlimited re-administration is expected to drive both incremental procedures and reinforce the therapy’s durability. Management views repeat dosing as a long-term volume driver, with minimal cannibalization risk and a meaningful “halo effect” supporting new patient starts.

2. Epioxa: Market Access and Launch Infrastructure

Epioxa, topical cross-linking therapy for keratoconus, is positioned as a category-defining product. Glaukos’ early investment in deploying O2N systems (capital equipment) to sites covering nearly half of the U.S. population and active engagement with major payers (including four of the top five commercial plans) is expected to accelerate patient access once the permanent J-code is effective in July. The company’s patient support and co-pay programs are designed to smooth the transition and minimize barriers to adoption.

3. International Glaucoma: Balancing Headwinds and New Launches

Outside the U.S., Glaukos is navigating competitive trialing headwinds while leveraging new product launches, such as Kysted Infinite, to sustain growth. Management expects international growth to moderate to high single digits, with a stronger first half due to currency tailwinds and new product momentum, followed by some deceleration as competitive activity intensifies.

4. Disciplined Capital Allocation and Pipeline Investment

Glaukos continues to invest heavily in R&D, with over $1 billion deployed since inception, supporting a robust pipeline spanning five therapeutic platforms. Operating expense growth will be in the mid-teens in 2026 to fund launches and pipeline milestones, but management is committed to achieving operating leverage and cash flow break-even by year-end.

5. Market Development and Education

Glaukos is actively investing in market development, physician education, and patient awareness, particularly for Epioxa and the broader interventional glaucoma paradigm. These efforts are expected to drive long-term shifts in standards of care and expand addressable markets.

Key Considerations

Glaukos’ Q4 and 2025 performance highlight a company in strategic transition, with near-term volatility in corneal health offset by durable growth in glaucoma and a robust innovation pipeline. The company’s execution on launch infrastructure, payer engagement, and patient access will be critical in realizing the full potential of its new therapies.

Key Considerations:

• iDose-TR Penetration Curve: Adoption remains early, with significant headroom as payer access expands and repeat dosing becomes more common.
• Epioxa Launch Ramp: Initial adoption will be gated by site deployment and payer approvals, with a pronounced back-half ramp once the permanent J-code is active.
• Operating Expense Management: Mid-teens OpEx growth in 2026 reflects heavy launch and R&D investment, but operating leverage is expected to emerge by year-end.
• International Dynamics: Competitive trialing will pressure growth in key markets, but new launches and market development efforts provide partial offsets.
• Pipeline Milestones: Multiple late-stage clinical programs across glaucoma, corneal, and retinal platforms position Glaukos for multi-year growth beyond current launches.

Risks

Key risks include potential delays in payer coverage or site deployment for Epioxa, competitive pressures in international glaucoma, and the challenge of balancing elevated launch spending with the goal of operating leverage. Regulatory or reimbursement setbacks, slower-than-expected adoption curves, or pipeline clinical failures could materially impact the growth trajectory. Management’s guidance assumes continued expansion of payer access and successful navigation of reimbursement transitions, both of which remain subject to external factors.

Forward Outlook

For Q1 2026, Glaukos expects:

• U.S. glaucoma revenue to be roughly flat sequentially, with iDose-TR growth offsetting seasonal headwinds in legacy products.
• Corneal health to see modest YoY growth, with a dip in Q2 as Epioxa transitions replace Photrexa procedures.

For full-year 2026, management reaffirmed guidance:

• Net sales of $600 to $620 million, implying over 20% growth at the midpoint.

Management highlighted several factors that will shape results:

• Sequential quarterly growth in iDose-TR throughout 2026, with a more back-half weighted contribution.
• Epioxa revenue ramping meaningfully in Q3 and Q4 as the permanent J-code is established and patient approvals accelerate.

Takeaways

Glaukos is executing a multi-pronged strategy to drive durable growth through innovation, payer access, and disciplined investment.

• iDose-TR is cementing its role as a transformative glaucoma therapy, with early adoption, positive clinical outcomes, and a repeat dosing label supporting long-term volume expansion.
• Epioxa’s launch is a pivotal moment for the corneal health franchise, with early infrastructure investments and payer engagement expected to drive a second-half inflection in adoption and revenue.
• Investors should monitor the pace of payer policy wins, operating expense leverage, and pipeline milestone execution, as these will determine the sustainability of Glaukos’ growth narrative into 2027 and beyond.

Conclusion

Glaukos’ Q4 and full-year 2025 results mark a turning point, with iDose-TR and Epioxa establishing new standards in ophthalmic care. The company’s disciplined approach to launch execution and capital allocation positions it for continued growth, though near-term volatility and execution risk remain as major launches ramp. The next 12 months will be critical in validating the company’s multi-year growth thesis.

Industry Read-Through

Glaukos’ successful iDose-TR ramp and Epioxa launch strategy signal a broader shift toward interventional, device-enabled, and patient-centric therapies in ophthalmology. The company’s experience underscores the importance of payer engagement, site deployment, and patient support in driving adoption of novel treatments. Competitors and adjacent medtech innovators should note the operational complexity and investment required to reshape standards of care and unlock new market opportunities. The transition from legacy therapies to next-generation interventions is accelerating, with implications for value-based care, reimbursement models, and long-term industry consolidation.

GKOS Healthcare Medical Devices Ophthalmology Glaucoma Keratoconus Innovation Payer Access